India’s largest state-run insurer, Life Insurance Corporation of India (LIC), has raised its stake in Dr. Reddy’s Laboratories to 8.21%, signaling strong confidence in the pharmaceutical sector.
🔴 Key Highlights:
- LIC acquired 1.67 crore equity shares of Dr. Reddy’s Laboratories through open market purchases.
- The stake increased from 6.204% to 8.216% between October 28, 2024, and June 3, 2025.
- Dr. Reddy’s share price surged over 4%, hitting ₹1,303.45 apiece on the BSE.
- LIC has been steadily increasing its stake, rising from 5.6% in September 2024 to 7.19% in March 2025.
📢 Market Experts Speak:
- “LIC’s growing stake reflects strong long-term confidence in Dr. Reddy’s business model and pharma sector growth.”
- “The stock has delivered a 40% return in two years and 60% in five years, making it a solid investment.”
⚠️ Strategic Impact:
- LIC’s move strengthens institutional backing for Dr. Reddy’s Laboratories.
- The pharma stock has gained 10% in the past month and 15% over three months, despite a 6% YTD decline.
👉 What do you think? Will LIC’s increased stake boost Dr. Reddy’s future growth? Drop your thoughts in the comments!
🔴 Share this post to keep investors informed! 🚀🔥
